Cancer-Cell Specific Organometallic Ru(II) Complexes as Photosensitizers in Photodynamic Therapy

Informazioni relative al progetto

OrganometRuPDT

ID dell’accordo di sovvenzione: 839499

DOI

10.3030/839499

Progetto chiuso

Data della firma CE 23 Aprile 2019

Data di avvio 1 Marzo 2020

Data di completamento 15 Luglio 2021

Finanziato da

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Costo totale

€ 107 746,24

Contributo UE

€ 107 746,24

Coordinato da

ECOLE NATIONALE SUPERIEURE DE CHIMIE DE PARIS
France

Periodic Reporting for period 1 - OrganometRuPDT (Cancer-Cell Specific Organometallic Ru(II) Complexes as Photosensitizers in Photodynamic Therapy)

Periodo di rendicontazione: 2020-03-01 al 2021-04-30

Sintesi del contesto e degli obiettivi generali del progetto

Cancer is still one of the most common and deadly diseases in the world. The current therapies usually have lots of side effects and some tumours are resistant to the most common therapeutics. Therefore, there is a need to tackle these problems and find out new strategies. Photodynamic therapy (PDT) is a promising therapy based in the combined effect of light, oxygen and a photosensitizer (PS). The non-toxic photosensitizer is excited and activated by light and this energy is transfered to oxygen, promoting singlet oxygen, extremely reactive species able to kill cells.
This therapeutic mechanism allows better specificity, since only the tumoral cells will be irradiated after the injection of the PS and therefore, it will reduce side effects in patients. Moreover, it will address the acquired resistance in some tumours, improving significantly the diagnosis of some patients.
The overall objective is the development of some metal complexes to be used as photosensitizers for PDT, including synthesis and characterization, and the test of these complexes in vitro first, and then in vivo.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The project has succeeded in the main objective: the design and synthesis of a metal complex, which absorbs in the red region of the spectrum. This is one of the most important features for the use of the metal complexes as photosensitizers for PDT. Then, the complexes were functionalised to an antibody (Ab) for selective deliver to cancer cells.
The exploitation will depend on the final results but the first approaches are promising. These results, in any case and always after publication or patent, will be disseminate in social networks, social media and in some conferences. Additionally, I will write a publication in my personal website: www.onepotscience.com.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

When finished, the project will have a huge impact in the improvement of cancer therapies. This will lead to a clear impact on society and how people with cancer can fight this disease. It will help not only general society, but also chemists, biochemists and doctors.
So far, we have succeed to connect a metal complex to a monoclonal antibody (mAb), what is one of the scarce examples of this kind of attachment/combination.
We are extremely excited about the final results, and hope to help a little bit in cancer research, and support cancer patients.

TOC graphics for the summary